Scholarlink

Objective <p>To explore the differentiation of airway inflammation, bronchial hyperresponsiveness and anti-asthma therapy responses between the cough variant asthma (CVA) and classic asthma (CA) patients with FEV<sub>1</sub>% ≥80% predicted.</p> Methods <p>In the first monocentre retrospective cross-sectional study, 402 patients with suspicion of CA and 544 patients with chronic cough were enrolled. Further prospective monocentre study was conducted and 66 patients of suspected asthma with negative bronchial dilation test (BDT) but positive bronchial challenge (BCT) test were enrolled and followed up for 4 weeks.</p> Results <p>CA patients had higher fractional exhaled nitric oxide (FENO) values than CVA patients (36.0 ppb vs. 24.0 ppb, <i>p</i> &lt; 0.0001). The predictive value of FENO for positive BCT was significantly lower in chronic cough patients compared to those with suspicion of CA (AUC = 0.603 vs. 0.728). Following four weeks anti-asthma therapy, both the CVA and CA groups showed significant improvement in both the large and small airway function and symptom relief. There was no significant difference between the respective groups. The two most valuable spirometric variables for predicting a positive response to anti-asthma treatment were the improvements of FEV<sub>1</sub> (ΔFEV<sub>1,</sub> cut-off values = 90&#xa0;ml for CA and 110&#xa0;ml for CVA) and FEV<sub>1</sub>% (ΔFEV<sub>1</sub>%, cut-off values = 3.49% for CA and 2.59% for CVA) after BDT in baseline of CA and CVA patients, respectively.</p> Conclusion <p>Patients with CVA exhibited lower levels of airway eosinophilic inflammation compared to those with mild CA. Most patients with mild CA and CVA could benefit promptly from anti-asthma treatment. Additionally, an improvement in FEV<sub>1</sub> and FEV<sub>1</sub>% during BDT can potentially predict positive responses to anti-asthma therapy in both groups.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Airway inflammation, bronchial hyperresponsiveness, and anti-asthma therapy responses in cough variant asthma and classic asthma with FEV1% ≥80% predicted

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月9日

查看全文
  • Xue Zhang,
  • Chengjian Lv,
  • Huijuan Hao,
  • Jingwang Lin,
  • Min Zhang,
  • Xue Tian

摘要

Objective

To explore the differentiation of airway inflammation, bronchial hyperresponsiveness and anti-asthma therapy responses between the cough variant asthma (CVA) and classic asthma (CA) patients with FEV1% ≥80% predicted.

Methods

In the first monocentre retrospective cross-sectional study, 402 patients with suspicion of CA and 544 patients with chronic cough were enrolled. Further prospective monocentre study was conducted and 66 patients of suspected asthma with negative bronchial dilation test (BDT) but positive bronchial challenge (BCT) test were enrolled and followed up for 4 weeks.

Results

CA patients had higher fractional exhaled nitric oxide (FENO) values than CVA patients (36.0 ppb vs. 24.0 ppb, p < 0.0001). The predictive value of FENO for positive BCT was significantly lower in chronic cough patients compared to those with suspicion of CA (AUC = 0.603 vs. 0.728). Following four weeks anti-asthma therapy, both the CVA and CA groups showed significant improvement in both the large and small airway function and symptom relief. There was no significant difference between the respective groups. The two most valuable spirometric variables for predicting a positive response to anti-asthma treatment were the improvements of FEV1 (ΔFEV1, cut-off values = 90 ml for CA and 110 ml for CVA) and FEV1% (ΔFEV1%, cut-off values = 3.49% for CA and 2.59% for CVA) after BDT in baseline of CA and CVA patients, respectively.

Conclusion

Patients with CVA exhibited lower levels of airway eosinophilic inflammation compared to those with mild CA. Most patients with mild CA and CVA could benefit promptly from anti-asthma treatment. Additionally, an improvement in FEV1 and FEV1% during BDT can potentially predict positive responses to anti-asthma therapy in both groups.